MESO NUMISMATICS, INC. Forward-Looking Statements
Certain statements, other than purely historical information, including
estimates, projections, statements relating to our business plans, objectives,
and expected operating results, and the assumptions upon which those statements
are based, are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends," "strategy," "plan,"
"may," "will," "would," "will be," "will continue," "will likely result," and
similar expressions. We intend such forward-looking statements to be covered by
the safe-harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995, and are including this
statement for purposes of complying with those safe-harbor
provisions. Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may cause actual
results to differ materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations
and future prospects on a consolidated basis include, but are not limited to:
changes in economic conditions, legislative/regulatory changes, availability of
capital, interest rates, competition, cybersecurity, and generally accepted
accounting principles. These risks and uncertainties should also be considered
in evaluating forward-looking statements and undue reliance should not be placed
on such statements. We undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise. Further, information concerning our business, including
additional factors that could materially affect our financial results, is
included herein and in our other filings with the
Overview
Since the acquisition of
We work with doctors and their staff to provide products, solutions, equipment, services, and training to help them be successful in the application of Stem Cell Therapies. Our team combines solutions from extensive clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever. Our strategy allows us the ability to create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform. Our revenue comes directly from the training and the seminars, from the resale of these kits, products, and equipment, services, and from the reoccurring application of our process using the kits and solutions we provide.
Page 29 of 41
The Company envisions the ability to improve "health-span" through the discovery and developments of new cellular therapy products, and cutting-edge technology.
We believe this strategy will allow us the ability to increase our current revenues and create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform here are our main projects and revenue generators for 2022 and beyond.
Results of Operations
Results of Operations for the Three Months Ended
Below is a summary of the results of operations for the three months endedJune 30, 2022 and 2021. For the Three Months Ended June 30, $ % 2022 2021 Change Change Revenue$ 304,521 $ 15,769 $ 288,752 1,831 % Cost of revenue 155,881 11,860 144,021 1,214 % Gross profit 148,641 3,909 144,732 3,703 % Operating expenses Advertising and marketing 80,961 144 80,817 56,123 % Professional fees 196,330 215,458 (19,128 ) -9 % Officer compensation 22,500 19,099 3,401 18 % Depreciation and amortization expense 35,325 200 35,125 17,562 % Investor relations 47,634 17,574 30,060 171 % General and administrative 131,304 5,945 125,359 2,109 % Total operating expenses 514,054 258,420 255,634 99 % Other income (expense) Interest expense (1,131,178 ) (440,457 ) (690,721 ) 157 % Derivative financial instruments 3,527 - 3,527 00 % Other expense - (231,109 ) 231,109 -100 % Net loss$ (1,493,065 ) $ (926,077 ) $ (566,987 ) 61 % Revenue
Revenue increased by 1,831% in the amount of
Page 30 of 41
Listed below are the revenues, cost of revenues and gross profits by Company for
the three months ended
For the Three Months Ended
June 30, 2022
Global Stem Meso
Cells Group Numismatics Total
Revenue $ 297,521 $ 7,000 $ 304,521
Cost of revenue 150,551 5,330 155,881
Gross profit $ 146,970 $ 1,670 $ 148,640
Gross profit % 49.40 % 23.86 % 48.81 %
We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.
Operating expenses
Operating expenses increased by 99% in the amount of
Advertising and marketing fees increased by
Depreciation and amortization increased by
General and administrative expense increase by
Other expense
Other expense increased by
Net Loss
We recorded a net loss of
Page 31 of 41
Results of Operations for the Six Months Ended
Below is a summary of the results of operations for the six months endedJune 30, 2022 and 2021. For the Six Months Ended June 30, % 2022 2021 $ Change Change Revenue$ 614,599 $ 20,212 $ 594,387 2,941 % Cost of revenue 359,474 26,650 332,824 1,249 % Gross profit 255,126 (6,438 ) 261,564 -4,063 % Operating expenses Advertising and marketing 135,575 381 135,194 35,484 % Professional fees 592,069 329,245 262,824 80 % Officer compensation 45,000 34,099 10,901 32 % Depreciation and amortization expense 62,302 400 61,902 15,476 % Investor relations 94,884 20,472 74,412 363 % General and administrative 233,222 16,555 216,667 1,309 % Total operating expenses 1,163,052 401,152 761,900 190 % Other income (expense) Interest expense (2,271,708 ) (759,685 ) (1,512,023 ) 199 % Derivative financial instruments 9,606 - 9,606 00 % Other expense - (231,109 ) 231,109 -100 % Net loss$ (3,170,028 ) $ (1,398,384 ) $ (1,771,644 ) 127 % Revenue
Revenue increased by 2,941% in the amount of
Listed below are the revenues, cost of revenues and gross profits by Company for
the six months ended
For the Six Months Ended
June 30, 2022
Global Stem Meso
Cells Group Numismatics Total
Revenue $ 596,270 $ 18,329 $ 614,599
Cost of revenue 343,035 16,439 359,474
Gross profit $ 253,235 $ 1,890 $ 255,125
Gross profit % 42.47 % 10.31 % 41.51 %
We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.
Page 32 of 41
Operating expenses
Operating expenses increased by 190% in the amount of
Advertising and marketing fees increased by
Professional fees increased by
Depreciation and amortization increased by
General and administrative expense increase by
Other expense
Other expense increased by
Net Loss
We recorded a net loss of
Liquidity and Capital Resources
Since inception, the Company has financed its operations through private
placements and convertible notes. The following is a summary of the cash and
cash equivalents as of
December 31, %
June 30, 2022 2021 $ Change Change
Cash and cash equivalents $ 1,924,532 $ 2,978,525 $ (1,053,993 ) -35 %© Edgar Online, source
